Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Xingcheng Biotechnology

Request full access

Cell and gene therapy CDMO services

Hangzhou, ChinaFounded 2021

About Hangzhou Xingcheng Biotechnology

Hangzhou Xingcheng Biotechnology, operating as CoJourney, is a Contract Development and Manufacturing Organization (CDMO) that provides services for cell and gene therapy companies worldwide. The company offers end-to-end process development, cGMP manufacturing, analytical method development, quality control testing, and product release for plasmids, viral vectors, and mRNA. Its business model is centered on providing custom-tailored, high-purity manufacturing solutions from development to GMP production.

CoJourney was founded by CEO Lijun Wang, who leads a management team with extensive operational experience in the global cell and gene therapy manufacturing sector. The company operates state-of-the-art cGMP manufacturing facilities in Hangzhou, China, and a process development center in Philadelphia, PA. In July 2023, CoJourney secured $30 million in a Series A financing round led by Legend Capital, with participation from GL Ventures, Legend Star Investment Management, and Lake Bleu Capital. This funding was aimed at expanding its US organization and commercial manufacturing capabilities, including a new facility at Spring House Innovation Park in Montgomery County, Pennsylvania.

The company's core services utilize proprietary platform technologies, including a notable "Zero Chrom Plasmid Platform" which reportedly reduces costs by up to 70% and production time by 60% while ensuring high purity. CoJourney's facilities are equipped with large-scale disposable bioreactors and fermenters to handle both clinical and commercial scale production, compliant with FDA, EMA, and NMPA regulations. The company has served over 40 clients and has successfully manufactured products approved for global clinical trials, including treatments for Neurovascular Age-Related Macular Degeneration in the USA and Spinal Muscular Atrophy in China.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
50.4/100

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2023 $28M $110M Kaitai Capital · LYFE Capital · BioTrack Capital · Legend Star ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Xingcheng Biotechnology website traffic

Latest recorded traffic for Hangzhou Xingcheng Biotechnology is 560 monthly website visits, down 53.3% over the last three months. Hangzhou Xingcheng Biotechnology's team grew 40% over the past year.

Latest monthly visits560 3-month web change-53.3% 1-year team growth+40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Xingcheng Biotechnology in the Hangzhou ecosystem

Live from Dealroom

The Hangzhou Xingcheng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China50%
🇺🇸 United States33.3%
🇬🇧 United Kingdom16.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Xingcheng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Xingcheng Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.